Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting shingosine kinase-1 - Leukemia
- ️Cuvillier, O
- ️Thu Nov 10 2005
Ogretmen B, Hannun YA . Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4: 604–616.
Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381: 800–803.
Perez GI, Knudson CM, Leykin L, Korsmeyer SJ, Tilly JL . Apoptosis-associated signaling pathways are required for chemotherapy- mediated female germ cell destruction. Nat Med 1997; 3: 1228–1232.
Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 2000; 6: 1109–1114.
Cuvillier O . Sphingosine in apoptosis signaling. Biochim Biophys Acta 2002; 1585: 153–162.
Spiegel S, Milstien S . Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 200; 4: 397–407.
Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S et al. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 1999; 147: 545–558.
Edsall LC, Cuvillier O, Twitty S, Spiegel S, Milstien S . Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells. J Neurochem 2001; 76: 1573–1584.
Nava VE, Hobson JP, Murthy S, Milstien S, Spiegel S . Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp Cell Res 2002; 281: 115–127.
Bektas M, Jolly PS, Muller C, Eberle J, Spiegel S, Geilen CC . Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 2005; 24: 178–187.
Cuvillier O, Levade T . Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood 2001; 98: 2828–2836.
Kleuser B, Cuvillier O, Spiegel S . 1a,25-dihydroxyvitamin D3 inhibits programmed cell death in HL-60 cells by activation of sphingosine kinase. Cancer Res 1998; 58: 1817–1824.
Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW et al. An oncogenic role of sphingosine kinase. Curr Biol 2000; 10: 1527–1530.
French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63: 5962–5969.
Chmura SJ, Nodzenski E, Beckett MA, Kufe DW, Quintans J, Weichselbaum RR . Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res 1997; 57: 1270–1275.
Michael JM, Lavin MF, Watters DJ . Resistance to radiation-induced apoptosis in Burkitt's lymphoma cells is associated with defective ceramide signaling. Cancer Res 1997; 57: 3600–3605.
Bruno AP, Laurent G, Averbeck D, Demur C, Bonnet J, Bettaieb A et al. Lack of ceramide generation in TF-1 human myeloid leukemic cells resistant to ionizing radiation. Cell Death Differ 1998; 5: 172–182.
Nava VE, Cuvillier O, Edsall LC, Kimura K, Milstien S, Gelmann EP et al. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res 2000; 60: 4468–4474.
Itoh M, Kitano T, Watanabe M, Kondo T, Yabu T, Taguchi Y et al. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin Cancer Res 2003; 9: 415–423.
Sonneveld P . Multidrug resistance in haematological malignancies. J Intern Med 2000; 247: 521–534.
Marquardt D, Center MS . Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells. Cancer Res 1992; 52: 3157–3163.
Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP . Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998; 91: 4480–4488.
Pitson SM, Moretti PA, Zebol JR, Xia P, Gamble JR, Vadas MA et al. Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase. J Biol Chem 2000; 275: 33945–33950.
Cuvillier O, Rosenthal DS, Smulson ME, Spiegel S . Sphingosine 1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas- and ceramide-mediated apoptosis in Jurkat T lymphocytes. J Biol Chem 1998; 273: 2910–2916.
Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S . Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem 1998; 273: 23722–23728.
Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 2000; 275: 19513–19520.
Perry DK, Bielawska A, Hannun YA . Quantitative determination of ceramide using diglyceride kinase. Methods Enzymol 2000; 312: 22–31.
Edsall LC, Spiegel S . Enzymatic measurement of sphingosine 1-phosphate. Anal Biochem 1999; 272: 80–86.
Aouali N, Morjani H, Trussardi A, Soma E, Giroux B, Manfait M . Enhanced cytotoxicity and nuclear accumulation of doxorubicin-loaded nanospheres in human breast cancer MCF7 cells expressing MRP1. Int J Oncol 2003; 23: 1195–1201.
Wu CH, Gordon J, Rastegar M, Ogretmen B, Safa AR . Proteinase-3, a serine protease which mediates doxorubicin-induced apoptosis in the HL-60 leukemia cell line, is downregulated in its doxorubicin-resistant variant. Oncogene 2002; 21: 5160–5174.
Wu CH, Rastegar M, Gordon J, Safa AR . beta(2)-microglobulin induces apoptosis in HL-60 human leukemia cell line and its multidrug resistant variants overexpressing MRP1 but lacking Bax or overexpressing P-glycoprotein. Oncogene 2001; 20: 7006–7020.
Taha TA, Osta W, Kozhaya L, Bielawski J, Johnson KR, Gillanders WE et al. Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J Biol Chem 2004; 279: 20546–20554.
Kono K, Tanaka M, Ogita T, Hosoya T, Kohama T . F-12509A, a new sphingosine kinase inhibitor, produced by a discomycete. J Antibiot (Tokyo) 2000; 53: 459–466.
Kono K, Sugiura M, Kohama T . Inhibition of recombinant sphingosine kinases by novel inhibitors of microbial origin, F-12509A and B-5354c. J Antibiot (Tokyo) 2002; 55: 99–103.
Deveraux QL, Reed JC . IAP family proteins-suppressors of apoptosis. Genes Dev 1999; 13: 239–252.
Sietsma H, Veldman RJ, Kok JW . The involvement of sphingolipids in multidrug resistance. J Membr Biol 2001; 181: 153–162.
Pallis M, Turzanski J, Higashi Y, Russell N . P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 2002; 43: 1221–1228.
Abe A, Shayman JA, Radin NS . A novel enzyme that catalyzes the esterification of N-acetylsphingosine. J Biol Chem 1996; 271: 14383–14389.
Kolesnick R . The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 2002; 110: 3–8.
Igarashi Y, Hakomori S, Toyokuni T, Dean B, Fujita S, Sugimoto M et al. Effect of chemically well-defined sphingosine and its N-methyl derivatives on protein kinase C and src kinase activities. Biochemistry 1989; 28: 6796–6800.
Khan WA, Dobrowsky R, el Touny S, Hannun YA . Protein kinase C and platelet inhibition by D-erythro-sphingosine: comparison with N,N-dimethylsphingosine and commercial preparation. Biochem Biophys Res Commun 1990; 172: 683–691.
Megidish T, White T, Takio K, Titani K, Igarashi Y, Hakomori S . The signal modulator protein 14-3-3 is a target of sphingosine- or N,N-dimethylsphingosine-dependent kinase in 3T3(A31) cells. Biochem Biophys Res Commun 1995; 216: 739–747.
Klostergaard J, Auzenne E, Leroux E . Characterization of cytotoxicity induced by sphingolipids in multidrug-resistant leukemia cells. Leuk Res 1998; 22: 1049–1056.
Jendiroba DB, Klostergaard J, Keyhani A, Pagliaro L, Freireich EJ . Effective cytotoxicity against human leukemias and chemotherapy-resistant leukemia cell lines by N-N-dimethylsphingosine. Leuk Res 2002; 26: 301–310.
Pallis M . Sphingosine kinase inhibitors in the apoptosis of leukaemia cells. Leuk Res 2002; 26: 415–416.
Endo K, Igarashi Y, Nisar M, Zhou QH, Hakomori S . Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethyl and N,N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. Cancer Res 1991; 51: 1613–1618.
Okoshi H, Hakomori S, Nisar M, Zhou QH, Kimura S, Tashiro K et al. Cell membrane signaling as target in cancer therapy II: inhibitory effect of N,N,N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor cell-dependent platelet aggregation. Cancer Res 1991; 51: 6019–6024.
Shirahama T, Sweeney EA, Sakakura C, Singhal AK, Nishiyama K, Akiyama S et al. In vitro and in vivo induction of apoptosis by sphingosine and N, N-dimethylsphingosine in human epidermoid carcinoma KB-3-1 and its multidrug-resistant cells. Clin Cancer Res 1997; 3: 257–264.